|
The following drug considerations were reviewed and determined
for formulary inclusion and tier placement by the U-M Pharmaceutical
Benefits Advisory Committee in August 2006.
| Drug Name |
|
PDL Class |
Action |
| Indication |
Yes/No |
| Azilect |
Parkinsons |
No |
Tier 3 |
| Sprycel |
HIV |
No |
Tier 2, eff 8-1-06 |
| Prezista |
HIV |
No |
Tier 2, eff 8-1-06 |
| Atripla |
HIV |
No |
Tier 3 |
| Zelapar ODT |
Parkinsons |
No |
Tier 3 |
| Retrovir |
HIV |
No |
Tier 3 eff 8-1-06, generic market entry |
| MetroLotion |
Rosacea |
No |
Tier 3 eff 8-1-06, generic market entry |
| Zithromax susp |
Antibiotic |
Yes |
Tier 3 eff 8-1-06, generic market entry |
| Zaditor OS |
allergic conjunctivitis |
No |
Tier 3 eff 8-1-06, generic market entry |
| Zoloft |
Antidepressant |
Yes |
Tier 3 eff 9-1-06, generic market entry |
| Effexor |
Antidepressant |
Yes |
Tier 3 eff 9-1-06, generic market entry |
| Plavix |
Antiplatelet |
No |
Tier 3 eff 9-1-06, generic market entry |
| Rhinocort Aqua |
Nasal Steroid |
Yes |
Tier 3, eff 10-1-06 |
| Nasacort AQ |
Nasal Steroid |
Yes |
Tier 3, eff 10-1-06 |
| Crestor |
Cholesterol |
Yes |
Tier 3, eff 10-1-06 |
| Advicor |
Cholesterol |
Yes |
Tier 3, eff 10-1-06 |
|
